Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMT-562 + LY2603618 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMT-562 | AMT 562|AMT562 | HER3 (ERBB3) Antibody 23 | AMT-562 is an antibody drug conjugate (ADC) comprising an ERBB3 (HER3) antibody conjugated to exatecan, which potentially inhibits tumor growth (PMID: 37302522). | |
LY2603618 | LY-2603618|Rabusertib | CHK1 Inhibitor 18 | Rabusertib (LY2603618) is a small molecule that inhibits CHK1, which may lead to disruption of DNA synthesis, early mitosis, and apoptosis, and may increase tumor cell sensitivity to chemotherapeutics (PMID: 24114124, PMID: 28625637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|